Brief: Nanobiotix Sings Strategic Royalty Monetization Agreement With Healthcare Royalty
31/10/2025 07:01
Oct 31 (Reuters) - Nanobiotix SA NANOB.PA: NANOBIOTIX ANNOUNCES STRATEGIC ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY FOR UP TO $71 MILLION AND EXTENDS CASH RUNWAY TOWARD LONG-TERM GROWTH FUNDING ENABLES NANOBIOTIX DEVELOPMENT IN CANCER MILESTONES HCRX TO RECEIVE CAPPED ROYALTIES ON JNJ-1900 SALES TO RECEIVE $50 MILLION UPFRONT, $21 MILLION LATER Source text: ID:nGNE6wcX7D Further company coverage: NANOB.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering